InnoCare get approval of Tafasitamab with Lenalidomide for the treatment of refractory diffuse large B-Cell lymphoma in Hong Kong
Tafasitamab is conditionally approved by both the U.S. Food and Drug Administration and European Medicines Agency
Tafasitamab is conditionally approved by both the U.S. Food and Drug Administration and European Medicines Agency
The company has plans to launch this Vaccine by the end of 2023 after completing the required field studies and obtaining regulatory approvals
Mock drills are being conducted across the country to review the preparedness for management of COVID-19
The company continue to develop this program for the WHO markets, thereby providing coverage and protection for more infants globally in time to come
Yonghe as the CDMO partner will provide production process development and cGMP manufacturing services for Ablaze
MindRank expects to initiate a Phase I safety study in the first quarter of 2023.
WHO made a strong recommendation for nirmatrelvir and ritonavir for mild and moderate COVID-19 patients at highest risk of hospital admission
Centre and states need to work in tandem and in a collaborative spirit as was done during the previous surges for COVID-19 prevention and management
Subscribe To Our Newsletter & Stay Updated